The group has canned its first-generation project, hoping that a follow-on will reach more patients.

LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.

An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.

The company makes no secret of the need for durability with its anti-CD47 project SL-172154.